In earlier reports, it has been shown that the loss of SETD2 resulted in a reduction of the H3K36me3 mark and accelerated tumor development60,61, suggesting a tumor-suppressor activity associated with H3K36me3 functioning in a critical but unknown locus. The gene discussed is SETD2; the disease is neoplasm.